GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
  • Research
    • Cross-cutting issues
      • Antimicrobial Resistance and Drug Discovery
      • Host–Pathogen Interactions
      • Genomic Surveillance and Population Mobility
      • Implementation and Translational Research
      • Information for Health Development
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • PRIME – Pathogen resistance, infection and molecular epidemiology
      • VBD – Vector borne diseases
      • CTM – Clinical tropical medicine
    • Research in numbers
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
    • BIOHUB & Available Software
    • BIOTROP Biobank
    • VIASEF & Insectaries
  • Networks & Partnerships
Home / Publications / Karavilagenin C derivatives as antimalarials.

Karavilagenin C derivatives as antimalarials.

  • Authors: Ferreira MJ, Lopes D, Molnar J, Mulhovo S, Ramalhete C, Rosário VE
  • Journal: Bioorganic & Medicinal Chemistry
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Karavilagenin+C+derivatives+as+antimalarials

Karavilagenin C (1), a cucurbitane-type triterpenoid, previously isolated from the aerial parts of Momordica balsamina, was acylated with different alkanoyl, aroyl and cinnamoyl chlorides/anydrides, yielding ten new mono or diesters, karavoates F (7) and H-P (8-16). Furthermore, the new compound cucurbalsaminol C (17) was isolated from the same plant. Their structures were assigned by spectroscopic methods, including 2D NMR experiments. Compounds 1 and 17 and the acyl derivatives 8-16 along with other five esters (2-6, karavoates A-E), previously prepared from 1, were evaluated for their in vitro antimalarial activity against the chloroquine-sensitive (3D7) and the chloroquine-resistant (Dd2) strains of Plasmodium falciparum. Compound 1 exhibited a moderate activity and 17 was inactive. However, a remarkable antiplasmodial activity was observed for most of karavilagenin C alkanoyl and monoaroyl/cynamoyl derivatives. Karavoates B, D, E, I, and M were the most active, displaying IC(50) values similar to those found for chloroquine, particularly against the resistant strain (IC(50) <0.6μM). Structure-activity relationships (SAR) are discussed. Moreover, the preliminary toxicity toward human cells of compounds 1-17 was also evaluated in breast cancer cell line (MCF-7). Most of the esters showed no toxicity, displaying, in general, much higher selectivity index values than those obtained for the parent compound.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Funding

UID/04413/2025 - DOI: 10.54499/UID/04413/2025

UID/PRR/04413/2025 - DOI: 10.54499/UID/PRR/04413/2025

UID/PRR2/04413/2025 - DOI: 10.54499/UID/PRR2/04413/2025

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.